UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 24, 2020

 

THERALINK TECHNOLOGIES, INC.

 

 

(Exact name of registrant as specified in its charter)

 

Nevada   000-52218   20-2590810
(State or other jurisdiction of   (Commission   (I.R.S. Employer
incorporation)   File Number)   Identification No.)

 

15000 W. 6th Ave., #400

Golden, CO 80401

(Address of principal executive offices)

 

(888) 585-4923

(Registrant’s telephone number, including area code)

 

ONCBIOMUNE PHARMACEUTICALS, INC.
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Today OncBioMune Pharmaceuticals, Inc. (the “Company”) announced that Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer, effective September 24, 2020. Mr. Kucharchuk will continue to serve as a director on the Company’s Board of Directors.

 

Thomas E. Chilcott, III, age 52, has been appointed Chief Financial Officer to serve effective September 24, 2020, until his resignation or removal by the Company. Immediately prior to joining the Company, Mr. Chilcott was the President of Chilcott Consulting Group (“Chilcott Consulting”), a financial and accounting services firm specializing in corporate restructuring and turnaround management. Prior to Chilcott Consulting, from January 2017 to June 2019, Mr. Chilcott worked for Ampio Pharmaceuticals, Inc. (“Ampio”), a publicly-traded development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options, where from June 2017 through June 2019 he served as their Chief Financial Officer, Secretary and Treasurer. From 2006 to his time at Ampio, Mr. Chilcott was the President of Chilcott Consulting. He also worked in public accounting for KPMG Peat Marwick where he was an Audit Senior Manager. Mr. Chilcott has a Bachelor of Science degree in Accounting from Villanova University and is a Certified Public Accountant in the State of Pennsylvania.

 

The Company entered into an offer letter with Mr. Chilcott which provides that his base salary will be $225,000 per year and that he will be eligible to receive the following bonuses: $5,000 if the Company’s next Annual Report on Form 10-K is filed on or prior to December 12, 2020; $5,000 if the Company files a registration statement on Form S-1 on or prior to January 15, 2021; $5,000 if the Company completes a capital raise of at least $3,000,000 on or prior to Apri1 15, 2021; $20,000 if the Company completes a capital raise of at least $10,000,000 on or prior to September 30, 2021; and $15,000 if the Company successfully lists on a Nasdaq stock market on or before December 31, 2021. Mr. Chilcott is entitled to participate in all medical and other benefits that the Company has established for its employees.

 

The offer letter also provides that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock at an exercise price and subject to the terms to be set by the Board of Directors of the Company.

 

Mr. Chilcott does not have any related party transactions or family relationships with the Company or any of the Company’s other officers or directors.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit No.   Description
99.1   Press release of Theralink Technologies, dated September 29, 2020

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  THERALINK TECHNOLOGIES, INC.
   
  By: /s/ Mick Ruxin, M.D.
  Name: Mick Ruxin, M.D.
  Title: Chief Executive Officer
   
Date: September 29, 2020 

 

 

 

 

Exhibit 99.1

 

 

 

Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer

 

DENVER, Colorado — September 29, 2020 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced the appointment of Thomas E. Chilcott, III CPA as Chief Financial Officer, effective September 24, 2020.

 

Mr. Chilcott joins Theralink Technologies with over 30 years of financial and operational experience in publicly traded and privately-owned companies. Throughout his career, Mr. Chilcott has provided guidance on capital formation, M&A, restructurings, and creating shareholder value. From 2017 to 2019, Mr. Chilcott was the Chief Financial Officer, Secretary and Treasurer of Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biotechnology company primarily focused on the development of therapies to treat prevalent inflammatory conditions. During his tenure at Ampio, he was instrumental in raising capital and leading the accounting and finance department including all SEC filings. Additionally, Mr. Chilcott, a CPA, was the President of Chilcott Consulting Group where for over 10 years he assisted many public and private biotechnology, healthcare and technology companies.

 

“We are pleased to welcome Tom to the Theralink team during this critical inflection point in our company’s history,” said Mick Ruxin, M.D., President and CEO of Theralink Technologies. “Tom will not only add to our team extensive public company experience in healthcare, but also a deep understanding of 3rd party reimbursement, capital formation and leadership, which will be critical to the sustained growth of our company in the future. I look forward to working closely with Tom as we execute on our strategic goals, growth and delivering shareholder value.”

 

Mr. Thomas Chilcott, newly appointed Chief Financial Officer, commented, “I look forward to complimenting the existing team at Theralink with my finance and operational experience. Theralink recently achieved a significant milestone of CLIA certification for its laboratory. We will immediately begin preparing to receive, test and bill for patient’s breast cancer tumor specimens during the fourth quarter of this year.”

 

About Theralink Technologies, Inc.

 

Theralink® Technologies is a CLIA accredited, proteomics-based, molecular profiling and precision medicine company located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and CLIA assay, Theralink’s technology targets multiple areas of oncology and drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.

 

Contact Information

 

Theralink Technologies, Inc.

KCSA Strategic Communications

Valter Pinto, Managing Director

212.896.1254

valter@kcsa.com